Mol Med Rep 21: [Related article:] 876-882, 2020; DOI:
10.3892/mmr.2019.10862
Following the publication of the above article on
modeling variants of adenosine deaminase 2 (ADA2), previously
identified by Gibson et al [Kristen M. Gibson, Kimberly A.
Morishita, Paul Dancey, Paul Moorehead, Britt Drögemöller, Xiaohua
Han, Jinko Graham, Robert E. W. Hancock, Dirk Foell, Susanne
Benseler, Rashid Luqmani, Rae S. M.Yeung, Susan Shenoi, Marek Bohm,
Alan M. Rosenberg, Colin J. Ross, David A. Cabral and Kelly L.
Brown: Identification of novel adenosine deaminase 2 gene variants
and varied clinical phenotype in pediatric vasculitis. Arthritis
Rheumatol 71: 1747-1755, 2019], (reference 18 in the article), Dr.
Kelly L. Brown, corresponding author of the Gibson et al
article, drew to the authors' attention possible discrepancies
identified therein. Upon examining the matters raised by Dr. K.
Brown, the authors wish to publish a corrigendum for this article,
and the following textual changes are required to the main
text.
The authors noted that it was not accurate to have
referred to the p.Gly47Arg mutation as being ‘novel’ when this
mutation was being specifically referred to, so the word ‘novel’
should have been omitted from the sentence in the abstract starting
on line 17: ‘This led to suggestions that the mutations found may
affect the formation/stability of the homodimer or may influence
the activity of the enzyme (15)’. However, Gibson et al in
their paper stated that ADA2 variant with the mutation Gly47Arg in
sera from homozygous individuals was a dimer (18). Also, the word
‘novel’ should not have been included in the title of Fig. 3, and
this should have appeared as follows: ‘Figure 3. The
DADA2-associated mutation G47R in the ADA2 structure’, and also,
for consistency, the titles of Figs. 4 and 5 should have been
written as ‘Figure 4. The DADA2-associated novel mutation R34W in
the ADA2 structure’ and ‘Figure 5. The DADA2-associated novel
mutation A357T in the ADA2 structure’. The authors would like to
add that the p.Arg34Trp variant's association with DADA2 has been
previously identified in a paper by Kaljas et al: Human
adenosine deaminases ADA1 and ADA2 bind to different subsets of
immune cells. Kaijas Y, Liu C, Skaldin M, Wu C, Zhou Q, Lu Y,
Aksentijevich I and Zavialow AV: Cell Mol Life Sci 74: 550-570,
2017.
In addition, the novel rare mutation identified by
Gibson et al as Arg9Trp associated with DADA2 lies in the
signal peptide [stated by the authors as Arg8Trp because Met#1 (ATG
start codon) is not included in the protein numbering] and is not
obviously included in the three-dimensional structure, and
therefore the authors did not deal with it. So, the sentence in the
Abstract starting on line 19 should have been written as follows:
‘It was thus concluded that the Gly47Arg mutation affects the
position and interaction of the dimer-associated HN1 helical
structure’. All references of Arg8Trp in the text, when referred to
the Gibson et al article, should be changed to Arg9Trp as
referred therein so as not to cause confusion.
Finally, in the legend for Fig. 2, ‘His358’ should
have been written as ‘His356’ (line 3), and for the purposes of
clarification, where ‘at the next Asn352 (2)’ was written at the
end of the same sentence, this text should be changed to ‘at the
neighboring glycosylated Asn378 [Asn352 in (2)]’. Similarly, on p.
880, the sentence at the end of the penultimate paragraph of the
Results section should have been written as follows: ‘This
disruption could be transmitted to the neighboring His356
coordinated to the metal ion or affect the confirmed glycosylation
at the neighboring glycosylated Asn378 [Asn352 in (2)]’.
The authors thank Dr. K. L. Brown for drawing these
matters to their attention, and emphasize that the resultant
corrections and clarifications do not alter either the results or
the main conclusions reported in the paper.
